

LUGPA 2022 Annual Meeting:

Independent Urology Powered by Innovation



Chicago Marriott Downtown Magnificent Mile Hotel 540 N Michigan Ave | Chicago



875 N. Michigan Avenue | Suite 3100 Chicago, IL 60611

www.lugpa.org






TAKE A CLOSER LOOK:

RECURRENCE INCIDENCE MAY BE HIGHER THAN YOU THINK

For certain patients with RCC after nephrectomy

An observational analysis using SEER-Medicare data¹ from 2007–2016, which included **643 patients**, revealed that...



of patients in this observational analysis with RCC post nephrectomy EXPERIENCED RECURRENCE¹

Of those patients who experienced recurrence,



HAD METASTATIC DISEASE¹

ANALYSIS POPULATION1:

- T2, grade 4, N0, M0; T3, N0, M0; T4, N0, M0; or T any stage, N+, M0.
- · Median follow-up duration of analysis was 23 months.

ANALYSIS LIMITATIONS¹:

- · Recurrence was inferred from the database codes rather than directly determined based on clinical data.
- The analyzed SEER-Medicare data represent patients ≥65 years. Hence, the results from this analysis may not reflect outcomes among the younger patient population.
- Impacts of recurrence may be confounded by unmeasured characteristics. Caution must be used when considering causal inference from this analysis.



Discuss this risk of recurrence with your appropriate patients with RCC post nephrectomy.

M0 = no distant metastasis; N0 = no regional lymph node metastasis; N+ = regional lymph node metastasis; RCC = renal cell carcinoma; SEER = Surveillance, Epidemiology, and End Results; T = primary tumor; T2 = tumor >7 cm in greatest dimension, limited to the kidney; T3 = tumor extends into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia; T4 = tumor invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland).

Reference: 1. Sundaram M, Song Y, Rogerio JW, et al. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: a retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data. *J Manag Care Spec Pharm.* 2022;28(10):1149–1160. doi:10.18553/jmcp.2022.22133






Table of Contents

Welcome	5
LUGPA Leadership	5
Welcome from Program Committee Chairman	7
LUGPA Committees	7
Meeting information	9
Pre-Meeting Program Agenda	10
Practice Administrators Workshop Agenda	11
CME Program Agenda	14
Research Directors and Coordinators Working Group Agenda	17
Radiation Oncology Providers Working Group Agenda	19
Medical Directors Working Group Agenda	20
Annual Meeting Program Agenda	23
Industry Sponsored Symposium Events	28
Thank You to Annual Meeting Sponsors	29
Thank You to Annual Meeting Exhibitors	30
Exhibit Hall Floor Plan	31
Keynote Biographies/Highlights	33
Faculty Biographies	37
Hotel Information/City of Chicago	47
Upcoming LUGPA Meetings	49
Sponsor Directory	50





Scan the QR code to discover more at LYNPARZAhcp.com





OFFICERS

President

Jonathan Henderson, MD Little Rock, AR

President-Elect

Evan Goldfischer, MD, MBA Poughkeepsie, NY

Secretary

Scott B. Sellinger, MD Tallahassee, FL

Treasurer

Dave Carpenter St. Paul, MN

Past President

Richard Harris, MD Melrose Park, IL

BOARD OF DIRECTORS

•

•

.

•

.

0

David M. Albala, MD, FACS Syracuse, NY

E. Scot Davis, MPA, MBA, CMPE Little Rock, AR

David J Ellis, MD, FACS Rosemont. PA

Michael D. Fabrizio, MD, FACS Virginia Beach, VA

Jason Hafron, MD Troy, MI

Mara R. Holton, MD *Annapolis*, *MD*

Jeffrey M. Spier, MD El Paso, TX

Alan D. Winkler, MHSA, FACMPE San Antonio, TX

Chief Executive Officer Celeste G. Kirschner, CAE

LUGPA 2022 Annual Meeting Welcome



Dear Colleagues:

On behalf of the LUGPA Board of Directors, welcome to the LUGPA 2022 Annual Meeting. As we come together to celebrate achievements as the only nonprofit trade association dedicated to the advancement and preservation of the independent practice of urology it is important to note that the Annual Meeting is LUGPA's most important event with education and networking available for our constituents: urologists, advanced practice providers, administrators, managers, and healthcare industry supporters.

This year's theme "Independent Urology Powered by Innovation" highlights how LUGPA groups have used creative ways to solve challenges and improve organizational performance. Whether it is identifying new services or processes to optimize practice efficiencies, embracing innovation will allow independent urology to thrive and adapt to the ever-changing healthcare environment. The Program Committee has organized an outstanding program for our members to experience world-class clinical education, professional and business development sessions, and updates on healthcare policy, political affairs, and practice benchmarking.

Over the next few days, it's important to remember that harnessing innovation is key to improving business outcomes. As you listen to a speaker, attend a breakout session, network during session breaks and at receptions, and talk with industry supporters in the Exhibit Hall, think about how you can create and sustain innovation in your practice. We hope that sessions on creative staffing models, restructuring care delivery and the openmic forum allows you to exchange ideas and implement new strategies that would benefit everyone; your practice, employees, and patients.

We would like to thank our industry supporters, for without their support, this meeting would not be possible.

Thank you for attending the LUGPA 2022 Annual Meeting, your membership and for your continued support.

Sincerely,

Jonathan Henderson, MD President, LUGPA




INJECTION FOR INTRAVENOUS USE 10 mg/mL

WHY WAIT?

LEARN WHERE YOU CAN START OPDIVO
IN THE TREATMENT CONTINUUM

Scan here to contact a BMS representative today.





LUGPA 2022 Annual Meeting Welcome



Welcome to the LUPGA 2022
Annual Meeting. We're excited to be back in Chicago to learn, exchange ideas and acknowledge all of the accomplishments of independent urology practices. Over the course of the three days, you will have the opportunity to experience world-class education, networking

and professional development. I am certain you will return to your practice with creative ideas and solutions acquired at this meeting to tackle the challenges that you face in your day-to-day role.

This year, our meeting theme is **Independent Practice Powered by Innovation** embraces LUGPA's commitment to transforming and sustaining innovation in independent practices of urology that includes continuing efforts to advance our political advocacy and our business and clinical knowledge. We have three keynote speakers that you will not want to miss. On Friday, political analyst Amy Walter, Editor-in-Chief of the Cook Political Report will enlighten us on her perspectives regarding current and future state of healthcare regulation and policy. Later in the day, entrepreneur and best-selling author Mr. Josh Linkner, will inspire you to create and nurture innovation in your practice. Finally on Saturday, political icon James Carville, will be sure to impress you with his entertaining stories of landslide victories.

On Friday the LUGPA Health Policy Committee will provide an update on regulatory and legislative polices that impact independent practices. You will also hear from Dr. David Albala who will provide highlights about LUGPA's Executive Leadership Program and the LUGPA Benchmarking Update session will provide information about the development of new metrics.

To customize your experience, this year we are happy to offer five breakout sessions on Saturday that you can choose from. The topics include: the ins and outs of mergers and acquisitions, addressing an active shooter, creative staffing models for recruitment and retention, and restructuring care delivery and the ever-popular "open mic" forum.

Prior to the official start of the annual meeting, on Thursday we are conducting our annual half-day continuing medical education program. Additionally, there is a full-day practice administrator program, along with special programming for research coordinators, lab directors and managers, medical directors, and radiation oncology providers.

In our exhibit hall, exhibitors will be present to discuss your unique practice challenges and answer your questions. Please review the 2022 exhibitor list in the program book and thank all of our industry supporters when you meet with them during the breaks. Without their support, this meeting would not be possible.

Finally, we have some elements of fun planned each day. On Thursday, all attendees are invited to the Networking Reception in the exhibit hall. Following dinner on your own, be sure to check out the LUGPA Forward reception "Mingle on the Magnificent Mile" later Thursday night. On Friday, all attendees are invited to the Welcome Reception, where you will have another opportunity to mingle with friends and visit with our valued exhibitors. Throughout the meeting there will be industry sponsored breakfasts and lunches for you to not only learn but to visit and catch-up with Industry Supporters and LUGPA members.

On behalf of the LUGPA Program Committee, thank you for attending the 2022 Annual Meeting. Please join us as we acknowledge our accomplishments and learning how to best position our independent group practices as we embark on another new and exciting year.

Sincerely,

Scott B. Sellinger, MD

Chair, LUGPA Program Committee

An A. fell To

PROGRAM COMMITTEE

Scott B. Sellinger, MD, FACS (Chair) Evan R. Goldfischer, MD, MBA Jonathan Henderson, MD Richard G. Harris, MD Alan D. Winkler, MHSA, FACMPE Victor Houtz, MBA, CPA Twila Puritty, MBA Jason M. Hafron, MD Andrew Pienkny, MD Vahan Kassabian, MD Dave M. Carpenter Michael D. Fabrizio, MD, FACS Joe Kuntze, MD Dave Morris, MD Ben Coons, MD Tom Rechtschaffen, MD Ravi Chauan, MD Matthew Whang, MD Dave Albala, MD Fernando Bianco,MD Jonathan Rushing Ben Lowentritt,MD



>> WHYYONSA?

Because it lets you explore the capabilities

OF A MICRONIZED ABIRATERONE ACETATE FORMULATION

Discover more at Booth #304.

>> Click to find out
>>> WHYYONSA?



Meeting Information All events will take place at the Chicago Marriott Downtown Magnificent Mile Hotel

••••••

REGISTRATION/INFORMATION DESK

Location: 7th Floor Check-in Desk (outside Grand Ballroom)

Wednesday, November 9, 2022

4:00pm - 7:00pm

Thursday, November 10, 2022

6:30am - 6:30pm

Friday, November 11, 2022

6:30am - 6:00pm

Saturday, November 12, 2022

6:30am - 12:45pm

SPEAKER READY ROOM

Location: Lincolnshire I & II (6th floor)

Thursday, November 10, 2022

7:30am - 5:15pm

Friday, November 11, 2022

6:30am - 6:00pm

Saturday, November 12, 2022

6:30am - 12:45pm

CME EXHIBIT HALL

Location: Grand Ballroom Foyer (7th Floor)

Thursday, November 10, 2022

12:00pm - 5:15pm

ANNUAL MEETING EXHIBIT HALL

Location: Chicago Ballroom (5th Floor)

Thursday, November 10, 2022

5:30pm - 6:30pm

Friday, November 11, 2022

7:30am - 6:00pm

MORNING EVENTS

Thursday, November 10, 2022

7:30am - 8:30am

Breakfast

Location: Avenue Ballroom (4th Floor)

EVENING EVENTS

Thursday, November 10, 2022

5:30pm - 6:30pm

Networking Reception

Location: Chicago Ballroom (5th Floor)

Sponsored by: Genentech

Thursday, November 10, 2022

9:00pm - 10:00pm

LUGPA Forward Reception "Mingle on the Magnificent Mile"

Location: Halsted (4th Floor)

Sponsored by: Myriad

Friday, November 11, 2022

5:00pm - 6:00pm

Welcome Reception

Location: Chicago Ballroom (5th Floor)

Sponsored by:

CardinalHealth

WIFI INFORMATION

Network Name: lugpa2022 Password: chicago2022

LUGPA 2022 ANNUAL MEETING APP

1. Download the Cvent Events app

On your mobile device, download the Cvent Events app from the App Store or Google Play.

2. Within the app, download the event

Once the app is open, search for the event ID MIW LUGPA2022 in the search bar (with a space after MIW) and tap the icon next to the event to download it. Allow notifications in order to get the latest updates and messages throughout the event.

3. Log in to the event

Tap the profile button at the bottom of the screen, then log in. Enter your first name, last name, and email address used for registration.

4. Verify your account

You will receive an email (check your junk mail too!)

and text message containing a verification code. Return to the app and enter the verification code to complete the login process and access the event.





Pre-Meeting Agenda

Wednesday November 9, 2022

TIME	SESSION TITLE	LOCATION	
4:00pm – 7:00pm	Registration/Information Desk	7th Floor Check-in Desk/Office	

Thursday, November 10, 2022 Overview

TIME	SESSION TITLE	LOCATION	
6:30am – 6:30am	Registration/Information Desk 7th Floor Check-in Desk/Office		
7:30am – 5:15pm	Speaker Ready Room	Lincolnshire I & II (6th Floor)	
7:30am – 5:15pm	Press Room	Denver/Houston (5th Floor)	
7:30am – 8:30am	Breakfast	Avenue Ballroom (4th Floor)	
8:30am – 11:15am	Radiation/Oncology Working Group Jeffrey Spier, MD	Northwestern/Ohio State (6th Floor)	
8:45am – 4:30pm	Practice Administrators Workshop Alan Winkler, MHSA, FACMPE	Marriott Ballroom (4th Floor)	
11:30am – 12:30pm	Industry Sponsored Breakfast Sponsored by: MERCK NVENTING FOR LIFE Grand Ballroom Salon III (7th Floridation Sponsored by: MERCK) Sponsored by: MERCK NVENTING FOR LIFE		
12:00pm – 5:15pm	CME Exhibit Hall	Grand Ballroom Foyer (7th Floor)	
12:45pm – 5:30pm	CME Program Neal Shore, MD I Gordon Brown, DO	Grand Ballroom Salons I & II (7th Floor)	
1:00pm – 5:15pm	Research Directors and Coordinators Working Group Twila Puritty	Indiana/Iowa (6th Floor)	
3:00pm – 5:15pm	Lab Directors and Managers Working Group Kirk Wojno, MD		
3:00pm – 5:15pm	Medical Directors Working Group Geoffrey Sklar, MD	Northwestern/Ohio State (6th Floor)	
5:30pm – 6:30pm	Networking Reception Chicago Ballroom (5th Floor) Sponsored by: Generatech Addender of the Roche Group.		
9:00pm — 10:00pm	LUGPA Forward Reception Mingle on the Magnificent Mile Sponsored by: Myriad genetics	Halsted (4th Floor)	

^{*}Topics and Speakers Subject to Change

Practice Administrators Workshop Agenda

Thursday, November 10, 2022


TIME	SESSION TITLE LOCATION		
7:30am – 8:30am	Breakfast	Avenue Ballroom (4th Floor)	
8:45am – 9:00am	Welcome and Introductions Alan D. Winkler, MHSA, FACMPE	Marriott Ballroom (4th Floor)	
9:00am – 9:45am	Sharknado: Healthcare Under Attack Presenter: Cameron Cox, MHA, FACMPE	Marriott Ballroom (4th Floor)	
9:45am – 10:00am	Break	Halsted (4th Floor)	
10:00am – 11:15am	The Three "R's" of Staff Compensation: Recruitment, Retention, Rewards Moderator: Alan D. Winkler, MHSA, FACMPE Panelists: Twila Puritty Claudio Zanin Jason Biddy	Marriott Ballroom (4th Floor)	
11:15am – 12:00pm	When to Hold; When to Fold: Addressing Disruptive Physician Behavior Presenter: Dave Carpenter	Marriott Ballroom (4th Floor)	
12:00pm – 1:00pm	Lunch	Avenue Ballroom (4th Floor)	
1:00pm – 2:00pm	Whats Keeping You Up at Night? Topic: PCR Implementation/Operation Facilitator: Dan Fellner, JD Topic: No Surprise Billing Act/ Implementation Challenges Facilitator: Sara Betancourt	Marriott Ballroom (4th Floor)	

^{*}Topics and Speakers Subject to Change

Practice Administrators Workshop Agenda: Thursday, November 10, 2022

TIME	SESSION TITLE	LOCATION	
	Topic: The Importance of a Strong Operating Agreement Facilitators: Carla Blue, FACMPE Whitt Holder Terry FitzPatrick		
2:00pm – 2:30pm	CCM/PCM – In-House vs. Outsourced: Medicare Requirements, Time Tracking, Billing and Staffing Panelists: Kirsten Anderson Lisa Baker Stephen Gabelich, MBA, FACHE, CMPE Kimberly Ramsey	Marriott Ballroom (4th Floor)	
2:30pm – 2:50pm	Break in the Exhibit Hall	Grand Ballroom Foyer (7th Floor)	
2:50pm – 3:30pm	Retiring Physicians: Lessons Learned Facilitators: E. Scot Davis Dave Carpenter Michael Shannon	Marriott Ballroom (4th Floor)	
CONCURRANT BREAKOUT SESSIONS			
3:30pm – 4:30pm	Negotiating Paid Physician Service Agreements with Community Hospitals Presenters: Angela Gilfillan LeeAnn Shea	Belmont (4th Floor)	
	New to LUGPA – What LUGPA Can Do for You Presenter: Terry FitzPatrick	Sheffield (4th Floor)	
	Shortcuts to Efficiency: Managing the Administrators' Growing Workload Presenter: John O'Connor	Armitage (4th Floor)	
	Optimizing Patient Place of Service Navigation: Clinic, ASC or Inpatient Presenters: Chris Setzler, MBA Mark Painter, CPMA, MBS	Marriott Ballroom (4th Floor)	

^{*}Topics and Speakers Subject to Change





Leading the Way to Optimizing Care in the Urology Practice

Thursday, November 10, 2022 Grand Ballroom Salons I & II (7th Floor)

TIME	SESSION TITLE
12:45pm – 1:00pm	Welcome and Introductions Neal Shore, MD, FACS Chair, LUGPA Education Committee and Co-Chair, CME Program Gordon Brown, DO, FACOS Co-Chair, CME Program
1:00pm — 1:58pm	Optimizing ASC Utilization Moderator: Michael Fabrizio, MD Robotic Surgery (prostatectomy and nephrectomy) Ronney Abaza, MD Percutaneous Upper Tract Management Julio Davalos, MD Urethral Reconstruction Brad Figler, MD Focal Therapies Fernando Bianco, MD Penile Implant-Post Prostatectomy Sherita King, MD Question and Answer
1:58pm – 2:26pm	BPH Treatments Moderator: Steven Kaplan, MD Deobstructing Mouse Traps Steven Kaplan, MD Prostate Artery Embolization Sandeep Bagla, MD Question and Answer Panelists: Samuel Hakim, MD David Morris, MD
2:26pm – 2:46pm	PSMA-PET Moderator: Evan Goldfischer, MD Clinical and Economic Utilization Phillip Koo, MD Question and Answer Panelists: E. Scot Davis Jeffrey Spier, MD David Albala, MD
2:46pm – 3:20pm	Break in the Exhibit Hall – Grand Ballroom Foyer (7th floor)

^{*}Please note that speakers and agenda topics are subject to change.

TIME	SESSION TITLE
3:20pm – 3:50pm	Appreciating Diversity in Urology Care Moderator: Neal Shore, MD, FACS
	Gender Affirming Surgery Brad Figler, MD
	LGBTQ Concerns Channa Amarasekera, MD Diana Bowen, MD
	Question and Answer Panelists: Guy Manetti, MD Michael Fabrizio, MD Benjamin Lowentritt, MD
3:50pm – 4:30pm	APCC Optimization Moderator: David Morris, MD mCSPC couplet vs triplets Alicia Morgans, MD
	mCRPC combining and sequencing Evan Yu, MD
	Genetic Testing Emmanuel Antonarakis, MD
	Question and Answer Panelists: Jonathan Henderson, MD Scott Sellinger, MD Jason Hafron, MD
4:30pm – 5:00pm	ABCC Optimization Moderators: Tom Jayram, MD
	Intravesical Explosion Colin Dinney, MD
	Systemic Therapies Arlene Siefker-Radtke, MD
	Question and Answer Panelists: Joshua Meeks, MD Suzanne Merrill, MD

^{*}Please note that speakers and agenda topics are subject to change.

TIME	SESSION TITLE
5:00pm – 5:25pm	Spacer Wars Moderator: Gordon Brown, DO, FACOS
	Barrigel Neil Mariados, MD
	SpaceOAR Parthiy Mehta, MD
	Bioprotect Edward Soffen, MD
	Question and Answer Panelists: Neil Mariados, MD Shawn Zimberg, MD Edward Soffen, MD Parthiy Mehta, MD
5:25pm – 5:30pm	Conclusion and Thank You Neal Shore, MD, FACS Gordon Brown, MD, FACOS



Research Directors and Coordinators Working Group



Indiana/lowa (6th Floor)

Agenda

Thursday, November 10, 2022 1:00pm – 5:15pm CT

Moderator:

Twila Purrity, CEO
Wichita Urology Group

Panelists:

Amanda Ho, Regulatory Specialist
Wichita Urology Group
Elizabeth Persels, Research Manager
Wichita Urology Group
Timothy A. Richardson, MD
Wichita Urology Group

1:00pm – 2:30pm Introductions and Panel Presentations

Regulatory

(Amanda Ho, Clinical Research Regulatory Specialist)

- Master Delegation of Authority Log
- Training Consistency
- · Policies and Procedures
- IND Safety Reporting
- 21CFR Part 11 Compliance and Electronic Signatures
- · Electronic Filing System: Do It Yourself
- Clinical Research
 (Elizabeth Persels, RN, Clinical Research Manager)
- · Contract and Budget Negotiations
- Best Price List
- Staff Retention and Incentives
- · Research Models

2:30pm - 3:00pm - Panel Presentation

 Physician's Perspective (Dr. Timothy A. Richardson)


3:00pm - 3:15pm - Break

3:15pm - 4:30pm - Open Mic

- Discussion Topics
- · Staff Retention and Incentives
- CTMS
- Budget and Contracts
- Regulatory

4:30pm – 5:15pm

Connect with Your Colleagues for Open Discussion and Networking



In the fight against genitourinary cancers,

YOUR COMMITMENT AND DEDICATION INSPIRE US.

We are proud to work with you.





Radiation Oncology Providers Working Group Agenda



Northwestern/Ohio State (6th floor)

Agenda

Thursday, November 10, 2022 7:30am – 11:15am CT

7:30am - 8:30am Breakfast in Halsted (4th floor)

8:30am – 8:35am Welcome and Introductions Jeffrey Spier, MD

Co-Moderator Shawn Zimberg MD Co-Moderator Ashley Ross MD

8:35am – 8:55am Enhancing the GU/Radiation Oncology Model

Presenters:

Ash Ross MD | Jeffrey Spier, MD

Panel Discussion: Sean Sachdev MD Travis Mendel MD Shawn Zimberg, MD

8:55am – 9:15am Next Generation Imaging

PSMA-PET/Nuclear Medicine/ Radiation

Oncology collaboration Presenter:

Phillip Koo, MD

9:15am – 9:40am Stereotactic Ablative Radiotherapy/ SBRT and Oligometastatic disease

Presenter:

Sean Sachdev MD

Panel Discussion: Shawn Zimberg, MD Neil Mariados, MD Travis Mendel, MD Ash Ross, MD Phillip Koo, MD 9:40am – 9:55pm – Interactive Break Novartis Presentation

9:55am – 10:10am Spacing: Referral Strategies/

Clinical Applications/Standardization

Presenter: Shawn Zimberg, MD

Panel Discussion:
Sean Sachdev, MD
Neil Mariados, MD
Shawn Zimberg, MD
Ash Ross, MD
Travis Mendel, MD

10:10am – 10:30am Current State of Adjuvant Radiotherapy Post Prostatectomy

Presenter: **Jeffrey Spier, MD**

10:30am – 11:05am Case Discussions/ Open Mic

Facilitator:

Jeffrey Spier, MD

Panel Discussion:
Sean Sachdev, MD
Neil Mariados, MD
Shawn Zimberg, MD
Ash Ross, MD
Phillip Koo, MD
Travis Mendel, MD
Daniel Spratt MD

11:05am – 11:15am Conclusion and Thank You Jeffrey Spier, MD

Medical Directors Working Group Agenda

Facilitator: Geoffrey Sklar, MD



Agenda

Thursday November 10, 2022 3:15pm – 5:15pm


Northwestern/Ohio State (6th Floor)

Review of 2022 Medical Director Survey

- Demographics
- · Staffing challenges
- · Physician Benefits and Recruitment
- Coding Reviews
- · Value Based Care Agreements
- Pathology Labs
- MolDx
- Pharmacy/IOD
- · IV Chemotherapy/Immunotherapy
- · Ambulatory Surgery Center
- CCM/PCM/TCM
- Telemedicine
- · Radiation Center
- · Hospital Call Coverage
- · Advanced Practice Provider

Interactive discussion of findings and primary pain points





LUGPA Annual Meeting Agenda

Friday November 11, 2022

TIME	SESSION TITLE LOCATION		
6:30am – 6:00pm	Registration/Information Desk	7th Floor Check-in Desk/Office	
6:30am – 6:00pm	Speaker Ready Room	Lincolnshire I & II (6th Floor)	
7:30am – 5:15pm	Press Room	Denver/Houston (5th Floor)	
7:30am – 8:30am	Industry Sponsored Breakfast Sponsored by: tolmar	Marriott Ballroom (4th Floor)	
7:30am – 8:30am	Industry Sponsored Breakfast Sponsored by: BAYER R		
7:30am – 6:00pm	Exhibit Hall	Chicago Ballroom (5th Floor)	
8:35am – 8:45am	Chair's Welcome and Introductions Scott Sellinger, MD, FACS	Grand Ballroom Salons I & II (7th Floor)	
8:45am – 8:50am	Presentation: Spirit of Independence Award Jonathan Henderson, MD	Grand Ballroom Salons I & II (7th Floor)	
8:50am – 9:15am	LUGPA Presidential Update Jonathan Henderson, MD	Grand Ballroom Salons I & II (7th Floor)	
9:15am – 9:30am	LUGPA/Specialty Network Collaboration Grand Ballroom Salons I & II (7th Jonathan Henderson, MD Darren Dieleman		
9:30am – 10:15am	LUGPA Health Policy Forum Moderator: Jonathan Henderson, MD Panelists: Mara R. Holton, MD Deepak Kapoor, MD Gary M. Kirsh, MD John McManus Elizabeth Barnett	Grand Ballroom Salons I & II (7th Floor)	
10:15am – 10:45am	Break in the Exhibit Hall	Chicago Ballroom (5th Floor)	

^{*}Please note that speakers and agenda topics are subject to change.

LUGPA Annual Meeting Agenda: Friday, November 11, 2022

TIME	SESSION TITLE	
10:45am – 11:15am	Political Analysis with Amy Walter	Grand Ballroom Salons I & II (7th Floor)
11:15am – 12:00pm	Q & A with Amy Walter and LUGPA's Health Policy and Political Affairs Team Moderators: Deepak Kapoor, MD Gary M. Kirsh, MD Panelists: Amy Walter Mara R. Holton, MD John McManus Elizabeth Barnett	Grand Ballroom Salons I & II (7th Floor)
12:00pm – 12:20pm	Political Affairs Update Gary Kirsh, MD	Grand Ballroom Salons I & II (7th Floor)
12:20pm – 12:30pm	Break/Transition Time	
12:30pm – 1:30pm	Sponsored by: Janssen	Marriott Ballroom (4th Floor)
12:30pm – 1:30pm	Industry Sponsored Lunch Sponsored by: MYOVANT Prizer	Grand Ballroom Salon III (7th Floor)
1:30pm – 1:40pm	Break/Transition Time	
1:40pm – 2:00pm	Highlights of the Executive Leadership Program David Albala, MD	Grand Ballroom Salons I & II (7th Floor)
2:00pm – 2:45pm	LUGPA Benchmarking Update Daniel Schonwald, CMPE Cass Schaedig	Grand Ballroom Salons I & II (7th Floor)
2:45pm – 3:45pm	BIG LITTLE BREAKTHROUGHS: How Small, Everyday Innovations Drive Oversized Results Sponsored by:	Grand Ballroom Salons I & II (7th Floor)
3:45pm – 4:15pm	Break/Transition Time	
4:15pm – 4:45pm	Annual LUGPA Business Meeting Jonathan Henderson, MD	Grand Ballroom Salons I & II (7th Floor)
4:45pm – 5:00pm	Break in Exhibit Hall	
5:00pm – 6:00pm	Welcome Reception Sponsored by: CardinalHealth Essented to core*	Chicago Ballroom (5th Floor)

^{*}Please note that speakers and agenda topics are subject to change.

Saturday, November 12, 2022

TIME	SESSION TITLE LOCATION		
6:30am - 12:45pm	Registration/Information Desk 7th Floor Check-in Desk/Offi		
6:30am – 12:30pm	Speaker Ready Room	Lincolnshire I & II (6th Floor)	
6:30am – 12:30pm	Press Room	Denver/Houston (5th Floor)	
7:30am – 8:30am	Industry Sponsored Breakfast Sponsored by: LANTHEUS	Grand Ballroom Salon III (7th Floor)	
8:30am – 8:45am	Break/Transition Time		
8:45am – 8:55am	Chair's Welcome and Friday Recap Scott Sellinger, MD, FACS	Grand Ballroom Salons I & II (7th Floor)	
8:55am – 9:00am	LUGPA Forward: Resident Clinical Innovation Award Presentation LUGPA Forward Chair, Tim Richardson, MD Resident Awardee: Kyle Waisanen, MD	Grand Ballroom Salons I & II (7th Floor)	
9:00am – 9:30pm	LUGPA Forward Presents: The Young Urologist's Roadmap to Success Moderator: Tim Richardson, MD Panel: Josh Langston, MD Jennifer Miles-Thomas MD Arash Rafiei, MD	Grand Ballroom Salons I & II (7th Floor)	
9:30am – 9:45am	Break/Transition Time	Grand Ballroom Salons I & II (7th Floor)	



CHECK OUT THE PRACTICE ADMINISTRATORS' ALLEY

5th Floor Alcove near the Chicago Ballroom

A place to network and meet with colleagues. A place to relax. Enjoy playing "Connect 4", Jenga or the Cornhole/Bags game.

Thursday November 10, 2022 | 5:30pm - 6:30pm Friday November 11, 2022 | 6:30am - 6:30pm Saturday November 12, 2022 | 6:30am - 11:00am

^{*}Please note that speakers and agenda topics are subject to change.

LUGPA Annual Meeting Agenda: Saturday, November 12, 2022

9:45am - 10:30am Breakout Session 1

Attendees: choose to attend one of the five breakouts

BREAKOUT I	BREAKOUT II	BREAKOUT III	BREAKOUT IV	BREAKOUT V
Location: Grand Ballroom Salons I & II (7th Floor) Open-Mic Richard Harris, MD	Location: Armitage (4th Floor) The Ins and Outs of Mergers and Acquisitions, Private Equity and Management Services Organizations Christopher M. Locke, JD	Location: Belmont (4th Floor) Developing a Plan to Address an Active Shooter Incident Ray Najera Jay Mroszczak	Location: Addison (4th Floor) Creative Staffing Models to Accelerate Recruitment and Improve Retention Dustin Knowles	Location: Clark (4th Floor) Restructuring the Care Delivery Model – Addressing Physician Shortages, Use of APP's and New Technologies Neal Patel, MD Chelsie Ferrell, PA Melissa Shanks, RN, BSN, MBA
10:30am – 10:45am	Break/Transition Time			

10:45am - 11:30am Breakout Session 2

Attendees: choose to attend one of the five breakouts

BREAKOUT I	BREAKOUT II	BREAKOUT III	BREAKOUT IV	BREAKOUT V
Location: Grand Ballroom Salons I & II (7th Floor)	Location: Armitage (4th Floor)	Location: Belmont (4th Floor)	Location: Addison (4th Floor)	Location: Clark (4th Floor)
Open-Mic Richard Harris, MD	The Ins and Outs of Mergers and Acquisitions, Private Equity and Management Services Organizations Christopher M. Locke, JD	Developing a Plan to Address an Active Shooter Incident Ray Najera Jay Mroszczak	Creative Staffing Models to Accelerate Recruitment and Improve Retention Dustin Knowles	Restructuring the Care Delivery Model – Addressing Physician Shortages, Use of APP's and New Technologies Neal Patel, MD Chelsie Ferrell, PA Melissa Shanks, RN, BSN, MBA
11:30am – 11:40am	Break/Transi	ition Time		
11:40am – 11:45am	Incoming Presidential Address		Grand Ballroom Salons I & II (7th Floor)	
11:45am – 12:30pm	Closing Keynote Presenter James Carville		Grand Ballroom Salons I & II (7th Floor)	
12:30pm – 12:45pm	Chair's Closing Remarks Scott Sellinger, MD, FACS		Grand Ballroom Salons I & II (7th Floor)	

^{*}Please note that speakers and agenda topics are subject to change.



PET/CT Imaging Agent



To find an Imaging Site near you, visit https://www.pylarify.com/site-locator

or scan this QR code with your smartphone or tablet







FOR INTRAVENOUS USE

BRIEF SUMMARY

Please see Full Prescribing Information available at www.lantheus.com/assets/PYLARIFY-Prescibing-Information.pdf for complete information.

INDICATION AND USAGE

PYLARIFY® (piflufolastat F 18) injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

CONTRAINDICATIONS

None

WARNINGS AND PRECAUTIONS

Risk of Image Misinterpretation

Imaging interpretation errors can occur with PYLARIFY imaging. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of PYLARIFY for imaging of patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. The performance of PYLARIFY for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by risk factors such as Gleason score and tumor stage. PYLARIFY uptake is not specific for prostate cancer and may occur with other types of cancer as well as nonmalignant processes and in normal tissues. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.

Hypersensitivity Reactions

Monitor patients for hypersensitivity reactions, particularly patients with a history of allergy to other drugs and foods. Reactions may not be immediate. Always have trained staff and resuscitation equipment available.

Radiation Risks

Diagnostic radiopharmaceuticals, including PYLARIFY, expose patients to radiation [see Dosage and Administration]. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration [see Dosage and Administration].

ADVERSE REACTIONS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of PYLARIFY was evaluated in 593 patients, each receiving one dose of PYLARIFY. The average injected activity was 340 ± 26 MBq (9.2 ± 0.7 mCi).

The adverse reactions reported in >0.5% of patients within the studies are shown in Table 2. In addition, a hypersensitivity reaction was reported in one patient (0.2%) with a history of allergic reaction.

Table 2. Adverse Reactions with a Frequency >0.5% in Patients Who Received PYLARIFY (n = 593)

Adverse Reaction	n (%)
Headache	13 (2%)
Dysgeusia	10 (2%)
Fatigue	7 (1%)

DRUG INTERACTIONS

Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of PYLARIFY in prostate cancer. The effect of these therapies on performance of PYLARIFY PET has not been established.

OVERDOSAGE

In the event of an overdose of PYLARIFY, reduce the radiation absorbed dose to the patient where possible by increasing the elimination of the drug from the body using hydration and frequent bladder voiding. A diuretic might also be considered. If possible, an estimate of the radiation effective dose administered to the patient should be made.

PATIENT COUNSELING INFORMATION

Adequate Hydration

Instruct patients to drink a sufficient amount of water to ensure adequate hydration before their PET study and urge them to drink and urinate as often as possible during the first hours following the administration of PYLARIFY, in order to reduce radiation exposure [see Dosage and Administration and Warnings and Precautions].

Manufactured for: Progenics Pharmaceuticals, Inc. 331 Treble Cove Road Billerica, MA 01862

PYLARIFY® is a trademark of Progenics Pharmaceuticals, Inc.

Patent: www.lantheus.com/patents/index.html



For ordering, tel. toll free: 800-299-3431 All Other Business: 800-362-2668 (For Massachusetts and International, call 978-667-9531)

Industry Events

Industry Sponsored Symposium Events



THURSDAY, NOVEMBER 10, 2022

11:30am - 12:30pm

Lunch

Location: Grand Ballroom Salon III (7th Floor)

Case-based Learnings on a Treatment Approach for Certain Patients With High-Risk NMIBC

Presenter: Alec S. Koo, MD



FRIDAY, NOVEMBER 11, 2022

7:30am - 8:30am

Breakfast

Location: Marriott Ballroom (4th Floor)

Topic:

Multidisciplinary Care Approach to the Management of Cardiovascular Risk for Patients on ADT

Presenter: Benjamin H. Lowentritt, MD, FACS

Sponsored by: tolmar

7:30am - 8:30am

Breakfast

Location: Grand Ballroom Salon III (7th Floor)

Topic:

NUBEQA® (darolutamide) **NOW APPROVED for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)** in Combination With Docetaxel

Presenter: Larry I. Karsh, MD

Sponsored by:



12:30pm - 1:30pm

Lunch

Location: Marriott Ballroom (4th Floor)

Optimizing Treatment with Precision Medicine in Metastatic Prostate Cancer

Presenters:

Benjamin H. Lowentritt, MD, FACS

Gordon A. Brown, DO David Morris, MD, FACS

Sponsored by: Janssen



12:30pm - 1:30pm

Lunch

Location: Grand Ballroom Salon III (7th Floor)

Topic:

A GnRH Antagonist Treatment Option for **Advanced Prostate Cancer**

Presenter: Bryan Mehlhaff, MD





SATURDAY, NOVEMBER 12, 2022

7:30am - 8:30am

Breakfast

Location: Grand Ballroom Salon III (7th Floor)

Topic:

PYLARIFY® PET/CT in Prostate Cancer Patients Combining the Accuracy of PET Imaging, the **Precision of PSMA Targeting and the Clarity of** an 18F Radioisotope

Presenter: Ashley E. Ross, MD

Sponsored by: LANTHEUS



Sponsors and Exhibitors

THANK YOU TO OUR MEETING SPONSORS AND EXHIBITORS

Platinum Level Partners

















Gold Level Partners

Silver Level Partners















Bronze Level Partners







THANK YOU TO OUR MEETING SPONSORS AND EXHIBITORS


Exhibitors

Acupath Laboratories, Inc./
KDx Diagnostics
Advanced Accelerator
Applications USA, Inc.
AmerisourceBergen
AngioDynamics
Blue Earth Diagnostics, Inc.
Bristol Myers Squibb
Cleveland Diagnostics, Inc.
Decipher Urologic Cancers
Dendreon
Pharmaceuticals, LLC
Endo Pharmaceuticals
Exosome Diagnostics
Fellow

Gemini Medical Technologies
GoPath Diagnostics
InMode
iSalus Healthcare
KOELIS
MDxHealth
MedEvolve
Medtronic
MenHealth
Meriplex Communications
Modernizing Medicine
P4 Diagnostix & PierianDx, Inc.
Pacific Edge Diagnostics
Palette Life Sciences, Inc.

Pathnostics
Preveta
Profound Medical
rater8
Siemens Healthineers
Specialty Networks, LLC
Streamline Scientific
Teleflex Interventional Urology
Telix Pharmaceuticals
Tempus Labs, Inc.
Zero – The End of
Prostate Cancer

Exhibit Hall Floor Plan



INDUSTRY PARTNER	Table #
AbbVie	309
Accord BioPharma	212
Acupath Laboratories, Inc./KDX Diagnostics	507
Advanced Accelerator Applications	206
AmerisourceBergen	509
AngioDynamics	403
Astellas Pharma and Pfizer Oncology	301
AstraZeneca	208
Bayer Oncology	511
Blue Earth Diagnostics, Inc.	210
Boston Scientific	503
	505
Bristol Myers Squibb	312
Cleveland Diagnostics, Inc.	102
Decipher Urologic Cancers	412
Dendreon Pharmaceuticals, LLC	407
Endo Pharmaceuticals	209
Exosome Diagnostics	113
Fellow	508
Gemini Medical Technologies	405
GoPath Diagnostics	409
ImmunityBio	406
InMode	207
iSalus Healthcare	411
Janssen Biotech, Inc.	201
KOELIS	308
Lantheus	302

INDUSTRY PARTNER	Table #
MDxHealth	305
MedEvolve	104
Medtronic	106
MenHealth	107
Merck	211
Meriplex Communications	501
Modernizing Medicine	303
Myovant Sciences, Inc. & Pfizer Oncology	307
Myriad Genetics, Inc.	402
	404
P4 Diagnostix & PierianDx	108
Pacific Edge Diagnostics	203
Palette Life Sciences	410
Pathnostics	112
Preveta	4
Profound Medical	205
rater8	5
Siemens Healthineers	514
Specialty Networks, LLC	500
Streamline Scientific	310
Sun Pharmaceuticals, Inc.	304
Teleflex Interventional Urology	204
Telix Pharmaceuticals	408
Tempus Labs, Inc.	306 202
Tolmar Pharmaceuticals, Inc.	311
UroGen Pharma, Inc. Urovant Sciences, Inc.	401
Zero – The End of Prostate Cancer	110
Zero - The End of Flostate Gancer	110



Introducing UroSuite

Prostate cancer testing, streamlined

Myriad's UroSuite gives health care providers the ability to directly order a complete suite of tests:

- Biomarker
- Germline
- Somatic NEW!

The only lab to offer comprehensive testing across the spectrum of prostate cancer care, along with best-in-class support and specialists.

Prolaris^c

BRACAnalysis CDx[®]/ MyRisk[™]

NEW! Precise™ Tumor

Diagnosis Treatment decision Recurrence/metastasis Clinical Trial

Comprehensive personalized care

Our offerings deliver genetic insight at every stage of the prostate cancer journey.

Peace of mind.

Prolaris is the only biomarker with two validated thresholds that provide better risk stratification at biopsy. Myriad has the most robust industry-leading variant classification program and rigorous verification system. This means that sending all tests-both tumor and germline-to Myriad solves the problem of lab discordance and qualifies more patients for targeted therapies and clinical trials.

Ease of ordering.

Ordering all tests through one company saves time and allows for a more efficient, streamlined process. The physician portal allows you to easily order multiple tests concurrently, and receive results with a simple summary sheet.


Access to genetic counselors.

Genetic counselors are available to provide educational support and answer questions at no cost.

Precise treatment registry.

UroSuite contributes to the healthcare community by providing access to data and analytics for independent research.





Health. Illuminated.

Keynote Speakers

Friday, November 11, 2022

10:45am – 11:15am: **Keynote Address**

11:15am - 12:00pm:

Q & A with Amy Walter and LUGPA's Health Policy and Political Affairs Team



Amy Walter
Publisher and Editor-in-Chief of the
Cook Report

For more than 25 years, Amy Walter has built a reputation as an accurate, objective, and insightful political analyst with unparalleled access to campaign insiders and decision-makers. Known as one of the best political journalists covering Washington, she is the

publisher and editor-in-chief of the non-partisan Cook Political Report with Amy Walter, where she provides analysis of the issues, trends, and events that shape the political environment. A contributor to the PBS NewsHour, she provides weekly political analysis for the popular "Politics Monday" segment and is a featured contributor for the network's election and convention special coverage events. She is also a regular Sunday panelist on NBC's Meet the Press and CNN's Inside Politics, and appears frequently on Special Report with Bret Baier on Fox News Channel. From 2017 until early 2021, Walter was the host of the weekly nationally syndicated program "Politics with Amy Walter" on The Takeaway from WNYC and PRX. She's also the former political director of ABC News.

In her presentations, Walter expertly breaks down the electoral process, congressional culture, and the Washington political scene. Her astuteness, wit, and range of expertise creates an engaging, compelling presentation, and her reliable and accurate analysis has earned her numerous accolades. Exclusively represented by Leading Authorities speakers bureau, Amy Walter takes audiences on an insider's tour of Washington through the eyes of the woman with her finger on the pulse of politics.

Political History. Before ABC, she was the editor-in-chief of *The Hotline*, Washington's premier daily briefing on American politics. There she served as the political publication's primary voice for three years, and she provided regular analysis of the national political environment in her weekly *National Journal* column, *On the Trail*. Walter has provided election night coverage and analysis since 1998 and was a member of CNN's Emmy-award winning election night team in 2006.

Accolades and Education. Named one of the "Top 50 Journalists" by Washingtonian magazine, as well as one of its "50 Most Powerful Women," Walter was dubbed one of the most powerful people in politics in George magazine for her insights into the mechanics that make the political machine run. She also won the Washington Post's Crystal Ball Award for her spot-on election predictions and has been frequently quoted as a congressional election expert in newspapers such as the Wall Street Journal, Washington Post, and the New York Times. Charlie Cook, Cook Political Report founder and contributor and political analyst for National Journal and NBC News, said, "Today,

her work is trusted and respected by Democrats and Republicans alike. She knows how to get beyond bluster and spin to unearth — and explain — what really matters in a political arena. And, she has a proven track record of success, which is essential for those whose jobs depend on accurate political forecasting."

Walter graduated summa cum laude from Colby College. She was also honored by her alma mater her with an honorary PhD, and now serves on the Board of Advisors. She is also a member of the Board of Advisors for the University of Chicago's Institute of Politics, where she was an inaugural fellow.

2:45pm – 3:45am: BIG LITTLE BREAKTHROUGHS: How Small, Everyday Innovations Drive Oversized Results



Josh Linkner
Chairman and co-founder of Platypus
Labs, an innovation-enablement,
research and consulting firm.

Mr. Linkner who started his career as a jazz guitarist – personifies innovation, entrepreneurship, and breakthrough disruption. He has been the founder and CEO of five tech companies, which sold for a combined value of over

\$200 million. Josh is a New York Times Bestselling author, and an internationally recognized expert on innovation and applied creativity. His first book, Disciplined Dreaming: A Proven System to Drive Breakthrough Creativity (2011), become one of the most definitive works on the topic of innovation, and has since been published in 13 languages. His other two books, The Road to Reinvention: How to Drive Disruption and Accelerate Transformation (2014), and Hacking Innovation: The New Growth Model from the Sinister World of Hackers (2017), have both received critical acclaim and have pushed the boundaries of business leaders worldwide. Josh is also the Founding Partner of Detroit Venture Partners, investing in and/ or mentoring over 100 startups. Today he serves as Chairman and co-founder of Platypus Labs, an innovation research, enablement and consulting firm. Josh has twice been named the EY Entrepreneur Of The Year and is a President Barack Obama Champion of Change Award recipient. He is a regular columnist for Forbes, the Detroit Free Press, and Inc. His work on innovation has been featured in The Wall Street Journal, Harvard Business Review, CNN, and The New York Times. He is the father of four, a passionate Detroiter, and yes, he still plays a mean jazz guitar.

Sponsored by:



Keynote Speaker

Saturday, November 12, 2022

11:45am – 12:30pm: James Carville Looks at Politics



James Carville
Political Icon

James "The Ragin' Cajun" Carville is America's best-known political consultant. His long list of electoral successes evidences a knack for steering overlooked campaigns to unexpected landslide victories and for re-making political underdogs into upset winners. His winning streak began in

1986, when he managed the gubernatorial victory of Robert Casey in Pennsylvania. In 1987, Carville helped guide Wallace Wilkinson to the governor's seat in Kentucky. Carville continued his winning streak with a win in New Jersey with Frank Lautenberg elected to the US Senate. He next managed the successful 1990 gubernatorial campaign of Georgia's Lieutenant Governor Zell Miller, including a tough primary win over Atlanta mayor Andrew Young, and in 1991, Carville – who had already become prominent in many political circles – drew national attention when he led Senator Harris Wofford from 40

points behind in the polls to an upset landslide victory over former Pennsylvania Governor and U.S. Attorney General Richard Thornburgh. But his most prominent victory was in 1992 when he helped William Jefferson Clinton win the Presidency. In recent years, Carville has not been a paid political consultant for many domestic politicians or candidates, instead focusing on campaigns in more than 23 countries around the globe stretching from the continents of South America to Europe to Africa and most recently Asia. James Carville is also a bestselling author, actor, producer, talk-show host, speaker and restaurateur. His titles include We're Still Right, They're Still Wrong: The Democrats' Case for 2016, Love & War: Twenty Years, Three Presidents, Two Daughters and One Louisiana Home; It's The Middle Class Stupid!; All's Fair: Love, War, and Running for President (with wife Mary Matalin); We're Right, They're Wrong: A Handbook for Spirited Progressives; And the Horse He Rode In On: The People vs. Kenneth Starr; Buck Up, Suck Up... and Come Back When You Foul Up; Had Enough? A Handbook for Fighting Back; Stickin': The Case for Loyalty; his children's book, Lu and the Swamp Ghost; and 2006's Take it Back, 40 More Years: How the Democrats will Rule the Next Generation. Along with pollster Stanley Greenberg, Carville founded Democracy Corps, an independent, non-profit polling organization dedicated to making government more responsive to the American people. Carville also serves as a professor of Practice at Tulane University in New Orleans, where he lives with his wife Mary Matalin and their two daughters.

LUGPA

EXECUTIVE LEADERSHIP PROGRAM

LUGPA's Executive Leadership Program is a 12-month comprehensive leadership development course designed specifically for independent urology group physicians and administrators.

Congratulations to the class of 2022 Executive Leadership Program.



Kevin Birusingh, MD Urologist, Urology Center of Iowa

Project Title:
Private Equity,
Management Services
Organizations and
Consolidation: Urology
and Healthcare State
of Affairs



Joshua Langston, MD Urologist, Urology of Virginia

Project Title:
Operational Excellence
"OP EX" in the
ASC Environment



Jason Poteet, MD Urologist, Urology Partners of North Texas

Project Title:
Increasing Ancillary
Utilization through
Physician to Physician
Intervention



Learn more about the 2022 class projects on

Friday November 11, 2022 at the Highlights of the

Executive Leadership Program" session scheduled

at 1:40 pm, and visit poster presentations in the

Grand Ballroom Fover, 7th floor.

Chris Webster, MD Urologist, Colorado Urology

Project Title:
Local Procedures in
the ASC: Cost and
Efficiency Analysis



Kimberly Zenkere Administrator, Oregon Urology Institute

Project Title: Implementing a Rapid Access Clinic



Mingle on the Magnificent Mile

LUGPA Forward Reception on THURSDAY, NOVEMBER 10

9:00pm – 10:00pm Halsted (4th Floor)

Sponsored by: Wyriad genetics



Congratulations to the
LUGPA 2022 Resident Clinical
Innovation Award Recipient

Kyle Waisanen, MD

PG-Y 5 Urology
University of Buffalo

Project Title:
Direct Urethral Sphincter Stimulation for
Stress Urinary Incontinence

Dr. Waisanen is a current chief resident with the University at Buffalo residency program. He graduated medical school at Ross University School of Medicine in 2017 and will be entering the Cleveland Clinic Florida urologic oncology fellowship starting July 2023.

Join us for the presentation of the Resident Clinical Innovation Award on Saturday November 12, 2022 | 8:55am Grand Ballroom Salons I & II Followed by:

LUGPA Forward Presents:

Saturday November 12, 2022:

The Young Urologist's Roadmap to Success

9:00am – 9:30am Grand Ballroom Salons I & II

Moderator:

Tim Richardson, MD

Panel:

Josh Langston, MD Jennifer Miles-Thomas, MD Arash Rafiei, MD



GALL YOUR OWN SHOTS.

Keep control and reliability in your hands.






✓ Proven efficacy **✓** Convenient dosing









Important Safety Information

ELIGARD®, (leuprolide acetate) for injectable suspension, is indicated for the palliative treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported. Visit EligardHCP.com for full **Prescribing and Safety Information.**

Reference: 1. Shore N, et al., BJU Int. 2016. 2. ELIGARD® (leuprolide acetate) for injectable suspension, 7.5 mg, 22.5 mg, 30 mg, 45 mg prescribing information. Fort Collins, CO: TOLMAR Therapeutics, Inc.: 2016



Faculty Biographies



LUGPA President Jonathan Henderson, MD

Dr. Henderson earned a Bachelor of Science Degree at LSU in Baton Rouge in microbiology. After receiving his MD at LSU Medical Center in Shreveport, he completed his internship and residency in Urology at LSUMC Hospital.

Dr. Henderson spent the next six years in practice in Alabama where he pioneered urologic laparoscopy. In 2002, Dr. Henderson was asked to return to Shreveport to join the nascent Regional Urology and served as CEO. In March 2022 Dr. Henderson joined Arkansas Urology in Little Rock, Arkansas Dr. Henderson is certified by the American Board of Urology. He is a member of the American Urologic Association (and sits on many committees for that organization), Shreveport Medical Society, Louisiana State Medical Society, and the Alpha Omega Alpha Medical Honor Society. He has been on the LUGPA Board of Directors since

2011 and is currently serving as President of LUGPA.



Program Committee Chair Scott Sellinger, MD

Dr. Sellinger has been a partner at Southeastern Urological Center, now a division of Advanced Urology Institute, since 1991. He received his B.S. degree in Chemistry from Syracuse University, and attended Medical School at the University of Florida in Gainesville. He completed his Urology

residency at the University of Florida and has lived in Tallahassee for over 30 years. He was President of the Capital Medical Society in 2003, and served as President of the Florida Urological Society in 2005. In 2018, he served as President of the Southeastern Section of the American Urological Association (SESAUA). In 2019, he served as President of the American Association of Clinical Urologists (AACU). In addition to his urology specific work, Dr. Sellinger has developed a special interest in risk management and prevention of medical errors and has lectured extensively on this subject matter. He is also interested in large group practice development and management. For several years, Dr. Sellinger has served on the board of Advanced Urology Institute (AUI) representing his care center in Tallahassee. In January 2021, he became the second President of AUI, now one of the largest independent urology practices in the United States. Dr. Sellinger currently chairs the Advanced Prostate Cancer (APC) Committee and oversees seven APC clinics within AUI. Since 2015, has also served on the Large Urology Group Practice Association (LUGPA) Board of Directors, where he currently serves as Secretary. At LUGPA, he is proud to represent over 2300 Urologists by working to preserve and advance the independent practice of urology.



David M. Albala, MD

Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth- Hitchcock Medical Center. Following this, Dr. Albala was an endourology fellow at Washington

University Medical Center under the direction of Ralph V. Clayman. He practiced at Loyola University Medical Center in Chicago and rose from the ranks of Instructor to full Professor in Urology and Radiology in eight years. Ten years later, he became a tenured Professor at Duke University Medical Center in North Carolina. At Duke, he was Co-Director of the Endourology fellowship and Director for the Center of Minimally Invasive and Robotic Urological Surgery. He has over 217 publications in peer-reviewed journals and has authored three textbooks in endourology and five in general urology. He is the Editor-in-Chief of the Journal of Robotic Surgery. He serves on the editorial board for Medical Reviews in Urology, Current Opinions in Urology and Urology Index and Reviews. He serves as a reviewer for eight surgical journals. He currently sits on the Board of Directors for the Large Urology Group Practice Association (LUGPA) as well as US Urology Partners (USUP). He is a Visiting Professor in the Department of Urology at SUNY Downstate Health Sciences University. In addition, he was ranked among the top 2% of urologists in the world by a Stanford University study done in May, 2021.

At the present time he is Chief of Urology at Crouse Hospital and a member of Associated Medical Professionals in Syracuse, New York. He is considered a national and international authority in laparoscopic and robotic urological surgery and has been an active teacher in this area for over 20 years. His research and clinical interests have focused on robotic urological surgery. In addition, other clinical interests include minimally invasive treatment of benign prostatic hypertrophy (BPH), biomarkers in prostate cancer, and the use of fibrin sealants in surgery. He has been a Visiting Professor at numerous institutions across the United States as well as overseas in countries such as India, China, Iceland, Germany, France, Japan, Brazil, Australia, and Singapore. In addition, he has done operative demonstrations in over 32 countries and 23 states. He has trained 19 fellows in endourology and advanced robotic surgery.

In addition, Dr. Albala is a past White House Fellow who acted as a special assistant to Federico Pena, Secretary of Transportation, on classified and unclassified public health related issues.



Elizabeth Barnett

Elizabeth Barnett is a Partner at Avenue Solutions, a government relations firm which provides strategic legislative, policy, and political expertise based in Washington, D.C. Elizabeth advises numerous clients across the spectrum of the health care industry on a range of federal legislative and regulatory issues related to Medicare, Medicaid, and the

Affordable Care Act. Elizabeth has over 20 years of experience in health care policy both in the private sector and on Capitol Hill. Before joining Avenue Solutions, Elizabeth was a lead Democratic lobbyist for the Blue Cross and Blue Shield Association. She had previously spent eight years working for U.S. Senator Blanche Lincoln (D-AR) as the Senator's principal health policy advisor.



Chelsie Ferrell, PA

Mrs. Ferrell received her Bachelor of Science Degree in Biology from the University of Missouri in 2009. She received her Masters of Science degree in Medical Science from Nova Southeastern University in 2013, where she was a Chancellors List Scholar.

She has been in the practice as a physician assistant since 2013. Her experience includes general urology. She is proficient in procedures such as cystoscopies & prostate biopsies and also has a special emphasis on advanced prostate cancer.

She is the chair of AUIs APP Committee and has experience as a national speaker/educator.



Richard Harris, MD President and CEO of UroPartners in Chicago, IL

Dr. Harris is a founding member and now the CEO and President of UroPartners, an integrated urology/ pathology/radiation oncology practice with over 60 physicians. He has been in the private practice of urology in Chicago for the last 31 years and

currently focuses on the treatment of prostate cancer, specifically metastatic castrate resistant prostate cancer.

Dr. Harris attended Washington University in St. Louis, and the Chicago Medical School. He completed his residency in general surgery and urology at Loyola University Medical Center.

Dr. Harris has been involved in pharmaceutical research and has performed over 100 clinical trials in drug development. He has served on LUGPA's Board of Directors for the last 10 years and is currently the Past President. Dr. Harris is also an assistant clinical professor of urology at Loyola University Medical Center.



Mara R. Holton, MD Founder and Director, Women's Wellness Center at Anne Arundel Urology

Dr. Mara Holton graduated from Temple University School of Medicine in 2001. She received her surgical and urology training at the University of Maryland Medical Center. She is certified by the American Board of Urology and is

licensed in the state of Maryland. She is clinically focused on the care of women's urological and pelvic floor health and has served as the CEO of her group, Anne Arundel Urology, for the past 4 years. She is a Board member of LUGPA, a member of the American Urological Association and is the founder and director of the Women's Wellness Center at Anne Arundel Urology.



Deepak A. Kapoor, MD

Dr. Kapoor is Chairman and Chief Ecosystem Officer of Solaris Health Holdings, LLC, Market President for Integrated Medical Professionals, PLLC (IMP) and President of Advanced Urology Centers of New York. His expertise includes basic science research in molecular biology, as well as extensive experience in

oncologic and reconstructive surgery.

Dr. Kapoor is Clinical Professor of Urology at the Icahn School of Medicine at Mount Sinai, Chair of the LUGPA Health Policy Committee, Past President of LUGPA, and Chairman of SCRUBS RRG. He has also served as a Director of UroPAC and Chairman of Access to Integrated Cancer Care. Dr. Kapoor was founder of the New York Urology Trade Association and Integrated Medical Foundation. In addition, he is a Fellow of the American College of Physician Executives.

Dr. Kapoor has published and lectured extensively on clinical, business and health policy issues and is Associate Editor of the journal Urology Practice. He serves on a number of medical advisory boards, including the New York State Governor's Prostate Cancer Advisory Panel. Dr. Kapoor has received numerous accolades, including the 2011 AUA Ambrose-Reed socioeconomic essay award, the 2014 New York Section AUA Russell W. Lavengood distinguished service award and was recognized in 2018 by LUGPA for outstanding contributions to health policy and the preservation of independent medicine.



Gary M. Kirsh, MD

Dr. Kirsh is the President of The Urology Group, a 35-urologist integrated group practice headquartered in Cincinnati, Ohio. He has served as the group's President since 2009. In 2008, Dr. Kirsh was instrumental in founding LUGPA. He has served as Secretary, President-Elect, and President (2014-2016) of LUGPA. Currently, Dr. Kirsh is the Chair

of the LUGPA Political Affairs Committee.

Dr. Kirsh has frequently spoken to urologists across the country on the socioeconomic and political issues facing urology and organized medicine. He has maintained longstanding relationships with various legislators and their staff, and has provided legislative testimony in support of physicians' issues at both the state and Congressional levels.

Clinically, Dr. Kirsh has special interest in prostate cancer and, more recently, in advanced prostate cancer. He is the director of the Advanced Prostate Cancer Clinic at The Urology Group and lectures often on this topic.

Dr. Kirsh earned his medical degree from the University of Chicago, Pritzker School of Medicine in 1984. He completed his urology residency at Case Western Reserve University in Cleveland, Ohio, in 1989. Dr. Kirsh resides in Cincinnati, Ohio with his wife Nora. Their two children reside in Boston and Washington, DC



Dustin Knowles

Dustin Knowles is the current Director of HR for Urology Centers of Alabama and has years of healthcare experience spanning Urology, Hospital, and Respiratory DME. HR labor relations in multiple industries has revealed to him that our people strategy is ever evolving, and like the healthcare our clinics provide, implementing innovative

solutions are necessary in staying ahead of the job market. Come by the *Creative Staffing Models to Accelerate Recruiting and Improve Retention* to find out how some of today's solutions have improved UCA's Team strategy.



Christopher M. Locke, JD

Mr. Locke is a Partner with Katten law firm. He specializes in health care. Health care entities trust Christopher with major transactions relating to their businesses. Deals that he works on regularly include purchases and sales of professional practices by private equity-backed entities (both seller and buyer sides), hospital system

acquisitions, joint ventures and other arrangements with professional practices, other hospital systems and universities, and regulatory and structural compliance for telehealth entities, in particular behavioral health. Negotiating and drafting these sometimes-complex agreements are just one aspect of Christopher's work. He is a trusted advisor, in part, because he provides as much business insight as legal counsel.



Joshua Langston, MD

Dr. Joshua Langston is a urologist and the Chief Medical Officer at Urology of Virginia, a 50 provider group based in Virginia Beach, VA. After residency training at the University of North Carolina – Chapel Hill, he completed a fellowship in Andrology & Male Reconstructive Urology at the Institute of Urology in London, England. His clinical practice

focuses on men's health and cancer survivorship, and he founded and directs Men's Health Virginia, a division of Urology of Virginia.

In addition to clinical pursuits, Dr. Langston has a strong interest in health policy, advocacy and physician leadership in medicine. He was selected as the American Urological Association's 2017 Holtgrewe Legislative Fellow, spending time as a health policy legislative advisor in the U.S. Senate. He is a member of the Political Affairs Committee for the Large Urology Group Practice Association where he was awarded their 2019 Advocate of the Year award. He is Co-Chair of the Regulatory Affairs Committee and a member of the Political Affairs and Practice Management Committees for the American Urological Association. While in the U.K., Dr. Langston was selected to participate in the Executive Mentoring Program sponsored by NHS England for doctors with special interest in executive leadership in medicine. He serves on the Board of Directors for the American Society for Men's Health, as well as a number of other boards and advisory groups.



John McManus

Mr. McManus is the President and founder of The McManus Group LLC, a consulting firm specializing in strategic policy, political counsel and advocacy for health care clients with issues before Congress and the Administration. The McManus Group services clients who are leaders in their respective field across the health care

spectrum from the pharmaceutical, biotechnology and medical device industries, to physician groups and employee benefit managers. The McManus Group was founded in 2004 and has built a reputation of substantive policy expertise that is trusted by key policy makers in both legislative chambers and in the Administration.

Before founding The McManus Group, Mr. McManus served Chairman Bill Thomas as the Staff Director of the Ways and Means Health Subcommittee, where he led the policy development, negotiations and drafting of the Medicare Prescription Drug, Improvement and Modernization Act of 2003. The MMA provided a market-based, comprehensive prescription drug benefit, reformed Medicare and established Health Savings Accounts. Mr. McManus worked for Chairman Thomas for six years where he also played an instrumental role in the Medicare Commission, Patients' Bill of Rights and other Medicare legislation.

Before working for Chairman Thomas on Capitol Hill, Mr. McManus worked for Eli Lilly & Company as a Senior Associate from 1994-97 and for the Maryland House of Delegates from 1993-94 as a Research Analyst, briefing the Chairman of the Economic Matters Committee and the members of the Health Subcommittee.

Mr. McManus earned his Masters of Public Policy from Duke University and Bachelor of Arts from Washington and Lee University. Mr. McManus serves on the Board of Advisors of the Williams School of Commerce, Economics and Politics of Washington and Lee University.



Jennifer Miles Thomas

Dr. Miles-Thomas earned her medical degree from Northwestern University Feinberg School of Medicine in Chicago, Illinois in 2001 after completing her undergraduate degree in Biology at Virginia Commonwealth University. She served her general surgery internship in the Department of Surgery at The Johns Hopkins Hospital

in Baltimore, Maryland, where she also completed her urology residency and fellowships in Female Urology and Endourology at The James Buchanan Brady Urological Institute. Dr. Miles-Thomas is a Diplomate of the American Board of Urology and is also board certified in Female Pelvic Medicine and Reconstructive Surgery. She is currently the CEO and President of Urology of Virginia and the Medical Director of the Pelvic Health program at Chesapeake Regional Healthcare. Dr. Miles-Thomas provides specialized care in female reconstructive surgery, pelvic prolapse, incontinence, complicated urinary disorders, and disorders of the urinary system due to neurologic disease.

She is a member of the American Urological Association (AUA), Mid-Atlantic Section of the AUA, Large Urology Group Practice Association (LUGPA), Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction, American Urogynecologic Society, and Society of Women in Urology.

Dr. Miles-Thomas has published several textbook chapters regarding voiding dysfunction. She has presented her research at numerous national and international medical conferences. She is also currently the Principal Investigator for many Overactive Bladder Trials at Urology of Virginia.



John J. (Jay) Mroszczak

Jay Mroszczak has been with the FBI Chicago for over six years, serving as both the Community Outreach Program Manager and as one of the Division's Crisis Response Team Managers. In addition, he is a member of the FBI Director's Advisory Council, and he was the Division's Diversity & Inclusion Coordinator for the last five years —

earning the Director's Award for Excellence in Diversity and Inclusion. During that time, he also served as the co-chair of the Veterans Affairs Advisory Committee of the Bureau's Diversity Action Council (DAC) for two years. Jay has over 40 years of professional experience working in National Security arena. Prior to joining the FBI in Chicago, Jay was an Executive Program Manager with Booz Allen Hamilton, managing several, strategic-level national security support programs. Jay is a trained member of the Bureau's Critical Incident Response Group (CIRG), and he has helped manage numerous Command Post (CP) activations in support of real-world incidents, as well as several CP training exercises. Before working for Booz Allen, Jay retired from the U.S. Army after 22 years as a senior-level, Combat Arms Officer, and he completed two combat deployments during his military tenure. Jay is a Chicago native and a graduate of Loyola University Chicago. He completed two master's degrees—one in Criminal Justice/ Criminal Law, and another in Government Program Management. He is also a Senior Fellow in National Security at the Kennedy School of Government, Harvard University.



Neal Patel, MD

Chief Technology Officer and Director of Robotic Surgery at Advanced Urology Institute of Georgia, PC in Snellville, GA.

Dr. Neal Patel, a Georgia native, earned his medical degree from Chicago Medical School as part of an engineering in medicine program with the Illinois Institute of Technology where

he graduated Cum Laude with a degree in Molecular Biochemistry and Biophysics. After completing residency in Urologic Surgery at Rutgers Robert Wood Johnson Medical School in New Jersey, he joined the USC Institute of Urology as a Felix and Mildred Yip Fellow in Advanced Robotics and Laparoscopy.

Dr. Patel has been active with the American Medical Association, the Illinois State Medical Society and the Chicago Medical Society. He has served on the Board of Trustees of the Chicago Medical Society, and has held multiple leadership positions within organized medicine at both local and national levels. In 2009, Dr. Patel was invited to attend the TEDMED inaugural conference in San Diego and has since been an invited alumnus.



Tim A. Richardson, MD

Dr. Richardson is a native of South-Central Kansas. He attended medical school at The University of Kansas from 1998-2002. He completed his urological surgery residency at The University of Nebraska Medical Center in 2008. Dr. Richardson was a partner at The Urology Center PC in Omaha before relocating to his hometown of Wichita

in 2012, when he joined Wichita Urology. He is board certified by the ABU and is a member of the AUA, AACU and SUO-CTC. He currently serves on the LUGPA Membership and LUGPA Forward Committees.

At Wichita Urology, Dr. Richardson serves on the Executive Committee, is the Advanced Prostate Cancer champion, co-director of clinical trials and director of the Xofigo infusion program. Dr. Richardson has served as a consultant and participated in numerous advisory boards regarding prostate cancer.



Arash Rafiei, MD

Dr. Rafiei received his Bachelors of Science in Physiology from University of California, Los Angeles (UCLA) in 2005. He attended Ross University School of Medicine, graduating in 2009. He completed his internship and residency in general surgery and urology, respectively, at the University of South Florida from 2009-2015. He joined Advanced Urology

Institute (AUI)following graduation and received his board certification by the American Urological Association (AUA) in 2017.

He currently serves on the board of directors of AUI. He is also the chair of AUI Forward committee and Solaris Future Leaders Committee and sits on the Solaris board of directors. He also serves on the LUGPA Political Affairs Committee and was the recipient of 2018 LUGPA Advocate of the Year Award. In addition, he has served on several committees of Florida Urological Society (FUS) including Executive Committee Board, Young Urology Committee and Legislative/Government Affairs Committee and is currently the FUS representative to SESAUA.



Cass Schaedig

With over 30 years in the healthcare industry, Cass Schaedig has perfected the ability to mine, synthesize and distill healthcare data to reveal and analyze the core functions of medical practices. Cass joined IntrinsiQ Specialty Solutions in 2015 and serves as Vice President of Provider Analytics. Equipped with the power of InfoDive® - the flagship

product of the company she founded in 1997 - Cass helps practices refine their operations to ensure peak efficiency and profitability. In past roles, Cass developed and delivered innovative solutions that addressed hospital and payer industry needs and challenges.



Daniel Schonwald, CMPE
Practice Administrator.

Comprehensive Urologic Care, SC in Lake Barrington, IL

As the Practice Administrator of Comprehensive Urologic Care, SC Mr. Schonwald believes in using technology and analytics to level the playing field between small practices and the large commercial payers, and innovating

health delivery systems to provide a rewarding environment for physicians and staff to deliver the best medical care to their patients.

Born and Raised in Oklahoma City, OK, Mr. Schonwald earned his Bachelor of Arts degree from Brandeis University in Waltham, Massachusetts. He has been a private practice executive for 14 years serving clinics in Oklahoma City and in Chicago, IL where he currently resides. He has obtained his Certified Medical Practice Executive certificate from MGMA.



Melissa Shanks, RN, BSN, MBA

Ms. Shanks is the Director of Operations at MN Urology. Her role connects the Metro Division teams including the locations of Coon Rapids, Fridley, Maplewood, St. Paul, Plymouth, and Woodbury. She supports patient services, clinical services, cancer programs, in-office dispensary, supply chain, and lab services. Melissa joined

Allina Health in 2019 bringing knowledge and experience from a background in Intensive Care and Trauma Nursing, Nursing Education, Specialty Care Operations Leadership and Oncology Care. She has a passion to improve patient experience through focusing on the efficiencies of the departments, implementing new processes and programs, and identifying ways to streamline patient care.

RADIATION AND ONCOLOGY PROVIDERS WORKING GROUP



Phillip J. Koo, MD

Dr. Koo is the Chief of Diagnostic Imaging and Physician Executive of Oncology at the Banner MD Anderson Cancer Center in Phoenix, AZ. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr. Koo completed his transitional internship at the University

of Pennsylvania Medical Center-Presbyterian, radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine. Dr. Koo's academic interests have focused on PET imaging in prostate cancer, response to novel therapies using PET, and data-driven image processing.



Neil Mariados, MD

Dr. Mariados has fellowship trained expertise in stereotactic radiosurgery and brachytherapy for head and neck, GI, breast, and prostate cancers. He works closely with thoracic surgeons regionally in utilizing stereotactic radiosurgery for lung tumors as well as IMRT.



J. Travis Mendel, MD

After graduating with a Bachelor of Science in Biochemistry, at the University of Puget Sound in Tacoma, Washington, he returned home to El Paso to pursue his Doctorate of Medicine at the Paul L. Foster School of Medicine at Texas Tech University Health Science Center. Following the completion of his degree in 2015,

he went on to do a transitional year internship at Tucson Hospital Medical Education Program in Arizona before returning to Texas for his residency in radiation oncology at UT Southwestern. He now brings his expertise to Rio Grande Urology.



Sean Sachdev, MD

Dr. Sachdev specializes in the treatment of brain and spine tumors (benign, malignant, or metastatic) and genitourinary (prostate, bladder and renal) cancers at Northwestern Feinberg School of Medicine. He is actively involved in translational research and bringing novel therapeutics to the clinic. He has an interest in synergistic

approaches utilizing highly-conformal image-guided radiotherapy.

Clinical Focus

Central Nervous System: Dr. Sachdev focuses on benign and malignant brain tumors, brain metastases, spinal cord tumors and vascular lesions (AVMs). He has expertise in the use of GammaKnife/stereotactic radiosurgery (SRS), spine stereotactic radiotherapy (SABR/SBRT) and image-guided highly-conformal radiotherapy.

Genitourinary: Dr. Sachdev focuses on prostate, bladder/urothelial, and renal cancers utilizing image-guided conformal dose-escalated radiotherapy for improved outcomes and better normal structure sparing. He has interest in the use of stereotactic radiotherapy (SABR/SBRT) for treatment of oligo-metastatic disease. He also maintains an interest in bladder preservation strategies that employ concurrent radiotherapy and chemotherapy in carefully selected patients.



Ashley Ross, MD

Dr. Ross is a surgeon scientist who specializes in urology and urologic oncology and is a nationally recognized expert in prostate cancer at Northwestern Feinberg School of Medicine. His research efforts focus on the development, testing and implementation of novel diagnostics and therapeutics with a goal of reducing the

suffering from prostate cancer. Clinically, Dr. Ross performs prostate cancer screening, prostate biopsy (including MRI-fusion biopsy), active surveillance, robotic prostatectomy, open radical prostatectomy, and ablative therapies of the prostate. Prior to joining the Feinberg School of Medicine, Dr. Ross served as director of the Johns Hopkins Urology Prostate Cancer Program, the executive medical director of the Mary Crowley Cancer Research Center, and an associate chair of the US Oncology Genitourinary Research Committee.

His research interests focus on both the epigenetics and genetic mutations associated with cancer biology. Specifically, he is studying how chromatin remodeling genes play a role in bladder cancer. In addition, he is investigating the "driver mutations found in bladder cancer. In the future, he hopes to develop novel systemic and intravesical therapies to improve survival of patients with bladder cancer.



Jeffrey Spier, MD

Dr. Spier is President of Rio Grande Urology (RGU) founded in 2008 serving West Texas and Southern New Mexico. RGU has 23 providers with 5 offices and 2 radiation centers employing over 250 staff in El Paso, Texas and Las Cruces, New Mexico. Dr. Spier has overseen the tremendous growth of RGU, becoming the largest private

practice physician group in the region. Rio Grande Urology continues to expand with the formation of the Rio Grande Cancer Specialists (RGCS) providing radiation therapy as well as the RGCS Advanced Prostate Cancer. This center of excellence includes clinical research with ongoing expansion into other genitourinary oncologic conditions. RGU is committed to serving the urologic and oncologic needs of our patients, providing state of the art and compassionate care.

Dr. Spier is board certified by the American Board of Urology and member of the American Urological Association and South Central Section of the AUA. He graduated from the University of Texas Medical Branch in Galveston, Texas where he also completed his Urology residency training. He currently serves on the Large Urology Group Practice Association (LUGPA) Board of Directors where he has served on multiple committees and is current chair the Membership Committee. He is currently President of the El Paso County Medical Society, board member of the University of Texas at Galveston Alumni Board of Trustees and has served on the board of the Texas Urological Society.



Daniel Spratt, MD

Dr. Spratt is the Chairman and Professor of Radiation Oncology at University Hospitals (UH) Seidman Cancer Center and Case Western Reserve University (CWRU). He obtained his medical degree from Vanderbilt Medical School and completed his radiation oncology residency at Memorial Sloan Kettering Cancer Center. He served

as the Vice Chair in the Department of Radiation Oncology and Chair of the Genitourinary Clinical Research Team at the University of Michigan until April 2021 when he joined UH and CWRU. Dr. Spratt is an international expert in the management of prostate cancer and the development and validation of prognostic and predictive biomarkers. He has published over 300 peer-reviewed manuscripts and runs a National Institute of Health-funded translational lab. He serves as the Chair for NRG Oncology's Intact Prostate Cancer Subcommittee, and for the National Cancer Institute's Genitourinary Steering Committee. He is the PI of numerous national and international randomized clinical trials in prostate and bladder cancer, and has mentored over 40 students and faculty.



Shawn Zimberg, MD

Dr. Zimberg is the Director of Radiation Oncology services at Integrated Medical Professionals. He board-certified in Radiation Oncology and has additional experience in investment banking. In the NY metropolitan area, he is recognized as a leader in the treatment of prostate, breast and head & neck cancers. He completed his

residency at Memorial Sloan-Kettering Cancer Center, where he was awarded the American Cancer Society's Clinical Oncology Fellowship. More recently, he was the recipient of the American Cancer Society's Cancer Control Award and currently serves on their Eastern Division's Advisory Board, where he held the position of Medical Spokesman from 2004-2006. Dr. Zimberg is a principal in Foundation Ventures, LLC, a NYC investment and merchant banking firm, where he is currently serving on their Health Science Advisory Board. Prior to residency, Dr. Zimberg was a medical advisor to Advanced Capital Resources, a private banking concern, where he specialized in medical device and biotechnology sectors. Dr. Zimberg received both his undergraduate and M.D. degrees from the University of Michigan, Ann Arbor.

LABORATORY DIRECTORS AND MANAGERS WORKING GROUP



Kirk J. Wojno, MD

Dr. Wojno is the founder and a coowner of MDpath (Michigan Digital Pathology) which is using digital pathology and artificial intelligence to transform the field of anatomic pathology. He also serves as CMO of Immunis.AI where he works closely with clinicians and laboratory scientists to develop and transform modern

molecular laboratory next generation sequencing patient data into relevant and clinically useful information that impacts patients' lives. As director of clinical research for Michigan Healthcare professionals he oversees numerous large scale multi-institutional clinical trials.

In addition to his work as the VPA laboratory director he has overseen the implementation of advanced molecular diagnostic testing for urinary tract infections, Covid19 testing as well as confirmatory toxicology testing. He has over 30 years of experience as laboratory, medical and clinical research director as well as faculty member and chief medical officer at various institutions including Michigan Healthcare Professionals, Comprehensive Urology, Pathnostics East, Progenity, Ameripath, Ascension Health System and the University of Michigan. He trained at the Johns Hopkins Hospital and is Board Certified in Anatomic and Clinical Pathology as well as Clinical Chemistry. He has published nearly 100 peer reviewed publications and numerous book chapters. He has extensive experience running molecular diagnostics laboratories.

Dr. Wojno has also served on scientific advisory boards and as a consultant to many of the top molecular diagnostic companies. He continues to educate the next generation of physicians and scientists and is a highly sought-after lecturer. He is also an active member of the College of American Pathologists as well as numerous other societies where he advocates for appropriate and ethical use of, as well as fair access to, advanced molecular laboratory testing. He truly strives to use his gifts to make a difference in patients' lives.

MEDICAL DIRECTORS WORKING GROUP



Geoffrey Sklar, MD, FACS

Dr. Sklar received his undergraduate training at the University of Maryland. He subsequently attended the University of Maryland School of Medicine and completed his urology residency at the University of Maryland Medical Center in 1994 and became a Diplomate of the American Board of Urology in 1996. He then became

faculty at the University of Maryland School of Medicine and ultimately appointed Chief of the Division of Urology and Residency Director at the University of Maryland School of Medicine. He subsequently joined Chesapeake Urology in 2006 and was appointed Chief Medical

Officer in 2009. Additionally, he was Chief of Urology and Director of Urologic Oncology, Associate Chief of Surgery, Chief of Credentials Committee and President of the Medical Staff of the University of Maryland Baltimore Washington Medical Center.

In July of 2017 Dr. Sklar became the Associate Director of the Weinberg Cancer Institute and Chief of the Division of Urologic Oncology at Medstar Franklin Square Medical Center. In 2018 Dr. Sklar was appointed Chief Medical officer of United Urology Group. He oversees risk management, quality assurance, compliance in his current role.

Dr. Sklar has more than 40 published manuscripts and has delivered over 500 lectures worldwide. He has participated more than 30 clinical trials. He was named an innovator in urology in 1997. Currently Dr. Sklar is a reviewer for the Journal of Urology, Urology Practice, Urology, the World Journal of Urology, the Journal of Sexual Medicine and the American Journal of Transplantation.

Dr. Sklar's clinical interests include: GU Oncology, Neobladders, Sexual function (ED, Peyronie's Disease), and genitourinary reconstruction. In addition to his interests in Urology, Dr. Sklar was a coach of an international martial arts team and coached many world champion martial artists.

RESEARCH DIRECTORS AND COORDINATORS WORKING GROUP



Amanda Ho

Amanda Ho is currently employed as the Clinical Research Regulatory Specialist at Wichita Urology Group in Wichita, Kansas. Amanda has over twenty-one years of experience in healthcare with twelve of that being in clinical research as a lead regulatory specialist. Amanda's prior experience includes serving as a Clinical Research

Regulatory Specialist in groups specializing in cardiology and medical oncology. Amanda's experience is currently being shared with a local nephrology practice.

In her two years with Wichita Urology Group, Amanda has successfully transformed clinical research's regulatory time management by revamping policies and procedures, creating new delegation of authority logs, converting a paper filing system to electronic files, and built a patient database from scratch.

Amanda's professional passions include teaching others, overcoming challenges, difficult conversations, and exchanging ideas with the top performers in research. She is overjoyed when teaching others time management ideas and her tips of the regulatory trade.

Amanda's enthusiasm to help others succeed is evidenced by her ability to meet others where they are in their regulatory journey. Over her career, she has provided one-on-one consultations with other regulatory specialists in diverse medical specialties. Amanda absolutely enjoys sharing her experience and knowledge with others.



Elizabeth Persels, RN

Elizabeth Persels serves as Clinical Research Manager of Wichita Urology Group, a research and comprehensive urology practice in Wichita, KS. Elizabeth has over 10 years of experience throughout 200+ multispecialty trials in clinical research. Prior to joining Wichita Urology, Elizabeth served as the lead clinical

research nurse and manager for cardiovascular research and multiple roles within oncology research.

During her time at Wichita Urology, Elizabeth has increased patient accrual, financial margins, promoted staff retention efforts, and has streamlined and created processes that have provided the exponential growth to the research department.

Elizabeth's professional passions include facilitating growth within the research community by assisting new program start-ups, contract and budget negotiations, and continual education to expand her knowledge and understanding of the research industry.



Twila Puritty, MBA

Twila Puritty is the CEO of Wichita Urology and has been with the practice for 9 years. Wichita Urology is a group of 15 providers with 3 locations in Wichita and 13 outreach locations in rural Kansas communities. Prior to joining Wichita urology, Twila had a 25+ year career managing radiology groups and imaging centers in Florida,

California, Oklahoma, Nebraska and Kansas.

In her nine years with Wichita Urology, the practice has grown by building a free-standing radiation oncology facility, adding a successful clinical trial program, establishing an advanced prostate cancer clinic, developing catheter dispensing, and in-office dispensing programs. The group recently opened a new 26,000 sq. ft. facility. The building houses a 14,000 sq. ft. ambulatory surgery center that opened the summer of 2021. Mrs. Puritty and the Wichita Urology physicians have also developed multiple LLCs for equipment and building leasing.

Twila's professional passions are facilitating growth initiatives, increasing clinical productivity, and enhancing collection efforts through microanalysis with the result of maximizing shareholder wealth.

Twila and her husband Ross have five children.





INNOVATION & INSPIRATION AWAIT

The experience starts here.



Hotel and City of Chicago Information

The Chicago Marriott Downtown Magnificent Mile hotel is located at 540 North Michigan Avenue, Chicago IL 60611. Reservation counter phone is 844-202-2203.

Check-in time: 4:00pm Central Time | Check-out time: 12:00pm Central Time

Amenities:

24-hour fitness center located on the 9th floor **Business center** located on the 2nd Floor.

Dining:

Rush Street Pantry – quick meals and snacks (located in the lobby area).

Reviver – bar and elevated street food (located in the lobby).

Parking:

Garage Self-Parking located at 50 East Ohio Street, Chicago, IL – discounted rate \$29 per day.

Valet parking is \$70 per day.

Public Transportation:

Chicago Transit Authority – Redline Train (Grand Avenue and State Street)

Amtrak and Metra – Union Station

Shopping:

The Shops at North Bridge – 520 North Michigan Ave. 900 North Michigan Shops (Bloomingdales building)– 900 North Michigan Ave.

City of Chicago Attractions

Navy Pier

700 E. Grand Ave.

American Girl Place

111 E. Chicago Ave.

Art Institute of Chicago

111 S Michigan Ave

Shedd Aquarium

1200 S. Lake Shore Dr. on the Museum Campus

Field Museum of Natural History

1400 S. Lake Shore Dr. on the Museum Campus

Adler Planetarium & Astronomy Museum

1300 S. Lake Shore on the Museum Campus

Merchandise Mart

350 N Wells

Museum of Science & Industry

5700 S. Lake Shore Dr.

Chicago Children's Museum

700 E. Grand Avenue, #127, Navy Pier

United Center (Bulls & Blackhawks)

1901 W. Madison

Soldier Field (NFL-Bears)

425 E. McFetridge Dr.

Chicago Architecture Foundation

224 S. Michigan Ave.

Lincoln Park Zoo/Conservatory

2200 N. Cannon Dr.

Chicago History Museum

1601 N Clark St

Museum of Contemporary Art

220 E. Chicago Ave.

MEET GEMTESA. CREATING POSSIBILITIES OVER AT BOOTH #401



Upcoming LUGPA Meetings



BLADDER & KIDNEY CANCER ACADEMY December 8 -10, 2022

Hotel ZAZA Memorial City, Houston, TX

REGIONAL MEETINGS January 21-21, 2023

Location: Grand Hyatt, Vail, CO

March 31- April 1, 2023

Location: Willard InterContinental,

Washington, DC

May 5-6, 2023

Location: Camelback Inn, Scottsdale, AZ

LUGPA UROLOGY 2023 RESIDENT SUMMIT AND JOB FAIR

March 3-4, 2023

Location: Fairmont Hotel, Chicago, IL

LUGPA 2023 ANNUAL MEETING

November 2-4, 2023

Location: Disney's Yacht & Beach Club Resort,

Orlando, FL

Sponsor Directory

AbbVie



AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases

Accord BioPharma



At Accord BioPharma, we think... about our patients' lives and perspectives, not just medicine and disease. Of doctors and clinicians as trusted partners, not as transactions. About delivering quality therapies that are affordable and accessible. About what comes before and after treatment, not just the drug.

We think beyond biology.

Astellas Pharma and **Pastellas** Pfizer Oncology





Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma.

AstraZeneca



AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

Bayer HealthCare



Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing aging population. Bayer is committed to the principles of sustaining development, and the Bayer brand stands for trust, reliability, and quality throughout the world. This information is intended for US healthcare providers only.

Boston Scientific



Boston Scientific partners with urologists to continually advance the quality of patient care with innovative urology solutions so you can choose the right technology and the right technique for every patient - without compromise. Visit our booth and speak with a representative to learn more.

ImmunityBio



ImmunityBio is a clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response.

Janssen Biotech, Inc.



At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.

Lantheus



With more than 60 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. For more information, visit www.lantheus.com.

Merck



At Merck our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer. Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

Myovant Sciences, Inc. and Pfizer Oncology



Myovant Sciences and Pfizer Oncology are working together to redefine care for millions of patients living with cancer and aspire to provide medicines that can improve lives and change treatment paradigms.

Myriad Genetics, Inc.



Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World's Most Innovative Companies for 2022. For more information, visit www.myriad.com.

Sun Pharmaceutical Industries Inc., USA



Sun Pharma is a wholly owned subsidiary of Sun Pharmaceutical Industries Limited (SPIL). SPIL is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. SPIL fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live. Company website address is https://sunpharma.com/usa/

TOLMAR Pharmaceuticals, Inc.



Committed to scientific advancement. Passionate about patient care. At Tolmar, science drives everything we do. We are dedicated to the development approval, and commercialization of specialty pharmaceutical products across the therapeutic areas of urology and oncology. Continuing to exceed the expectations of our clients and their patients is our promise.

UroGen Pharma, Inc.



UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed a proprietary innovative technology platform, RTGelTM, a reverse-thermal sustained-release, hydrogel that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to work with the urologic anatomy—not against it—enabling longer exposure of the urinary tract tissue to medications and making local therapy a potentially more effective treatment option.

UroGen's first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

Urovant Sciences, Inc.



Urovant Sciences is a biopharmaceutical company focused on developing and commercializing therapies for patients. Urovant Sciences, a subsidiary of Sumitomo Pharma Co., Ltd., intends to develop treatments for additional diseases. Learn more about us at www.urovant.com



APPROVED FOR A NEW INDICATION



Learn More at NUBEQAhcp.com

EXPERIENCE NUBEQA® NOW

30-DAY
FREE SAMPLE PROGRAM

Ordering a sample is simple...

Contact your sales representative, who will process your sample request.



LUGPA Featured Programs and Products



Not a member of LUGPA's Benchmarking program? It's not too late to join. For those who participate in the program, InfoDive®, IQSS' business analytics solution, provides a HIPAA-compliant secure data exchange from various practice management systems to benchmark productivity, financial, and coding metrics for practice, provider, and patient-level data. These insights will allow for strategic reporting of urology-specific benchmarks and help your practice identify potential opportunities for performance improvement and risk mitigation.

These benchmarking metrics will also assist LUGPA in providing educational and research programs as well as provide analytical support to key LUGPA health policy initiatives.


With InfoDive, you gain more than just benchmarking insights. As a participating practice, you gain valuable insight into practice performance that will allow you to:

- Analyze key financial metrics that can help with payer negotiations
- Compare coding patterns to help mitigate audit risk
- Evaluate net cost recovery based on adjudicated claims, invoice cost, and rebates through InfoDive's Buy and Bill report
- Uncover inaccurate or missed drug billing opportunities, revenue leakage, and compliance issues with InfoDive's GapFinder®
- Access robust profiling of new patients, referrals, and patient demographics to target marketing efforts
- Monitor your fee schedule to identify underpriced services
- Access urology-specific reports including Stent Removal Tracking, Prostate Biopsy Analysis, Prostate Cancer Analysis, Stone Treatment Profile, and American Board of Urology Report

For more information on the benchmarking program and how to join, please contact **Kathy Stack** at **kstack@lugpa.org** or **312.728.0137**. If you are not a current InfoDive user and would like more information or a product demonstration, please contact **info@intrinsiq.com**.

LUGPA Featured Programs and Products





Practice Management for Urology Groups Second Edition of LUGPA's Guidebook NOW AVAILABLE!

Featuring 14 New Chapters!

LUGPA's Guidebook is a collaboration of expert advice authored by LUGPA's urology specialists, and provides invaluable guidance to help urology practices navigate healthcare challenges and thus create their own effective solutions. LUGPA members can receive free digital access [login required]. Printed copies can be ordered on Amazon.com for a special show price of \$125.




SRC/NAFC Center of Excellence In Continence Care for Women

Surgical Review Corporation (SRC) and the National Association for Continence (NAFC) have collaborated to create a Center of Excellence in Continence Care for Women (COECCW) accreditation program. Center of Excellence programs recognize hospitals, ambulatory surgical centers and specific medical professionals from their service lines who are committed to achieving defined standards for patient safety and care quality

To learn more go to:

https://lugpa.memberclicks.net/src-nafc-coe-in-continence-care













Physician Ownership | Independence | Clinical Expertise

Solaris Health is committed to preserving and advancing independent urology. We partner with local affiliates to provide the knowledge and resources necessary to thrive in the rapidly evolving U.S. healthcare market.

